Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Immunocore Holdings plc or Bausch Health Companies Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Immunocore Holdings plc and Bausch Health Companies Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Immunocore Holdings plc and Bausch Health Companies Inc.

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Latest Biotechnology and Immunocore Holdings plc, Bausch Health Companies Inc. Stock News

As of July 31, 2026, Immunocore Holdings plc had a $1.7 billion market capitalization, compared to the Biotechnology median of $252.6 million. Immunocore Holdings plc’s stock is down 2.6% in 2026, down 3.4% in the previous five trading days and up 0.93% in the past year.

Currently, Immunocore Holdings plc does not have a price-earnings ratio. Immunocore Holdings plc’s trailing 12-month revenue is $412.8 million with a -6.7% net profit margin. Year-over-year quarterly sales growth most recently was 13.6%. Analysts expect adjusted earnings to reach $0.134 per share for the current fiscal year. Immunocore Holdings plc does not currently pay a dividend.

As of July 31, 2026, Bausch Health Companies Inc. had a $2.6 billion market cap, putting it in the 57th percentile of all stocks. Bausch Health Companies Inc.’s stock is down 0.9% in 2026, up 55.5% in the previous five trading days and up 7.83% in the past year.

Currently, Bausch Health Companies Inc. does not have a price-earnings ratio. Bausch Health Companies Inc.’s trailing 12-month revenue is $10.9 billion with a -10.1% net profit margin. Year-over-year quarterly sales growth most recently was 12.7%. Analysts expect adjusted earnings to reach $4.301 per share for the current fiscal year. Bausch Health Companies Inc. does not currently pay a dividend.

How We Compare Immunocore Holdings plc and Bausch Health Companies Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Immunocore Holdings plc and Bausch Health Companies Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Immunocore Holdings plc and Bausch Health Companies Inc. Stock Value Grades

Company	Ticker	Value
Immunocore Holdings plc	IMCR	F
Bausch Health Companies Inc.	BHC	A

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Immunocore Holdings plc has a Value Score of 19, which is Ultra Expensive. Bausch Health Companies Inc. has a Value Score of 95, which is Deep Value.

The Value Stock Winner: Bausch Health Companies Inc.

As you can clearly see from the Value Grade breakdown above, Bausch Health Companies Inc. is considered to have better value than Immunocore Holdings plc. For investors who focus solely on a company’s valuation, Bausch Health Companies Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Immunocore Holdings plc and Bausch Health Companies Inc. Growth Grades

Company	Ticker	Growth
Immunocore Holdings plc	IMCR	D
Bausch Health Companies Inc.	BHC	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Immunocore Holdings plc has a Growth Score of 26, which is Weak. Bausch Health Companies Inc. has a Growth Score of 40, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither Immunocore Holdings plc or Bausch Health Companies Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Immunocore Holdings plc or Bausch Health Companies Inc. is the better investment when it comes to sustainable growth.

Immunocore Holdings plc and Bausch Health Companies Inc.’s Quality Grades

Company	Ticker	Quality
Immunocore Holdings plc	IMCR	D
Bausch Health Companies Inc.	BHC	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Immunocore Holdings plc has a Quality Score of 29, which is Weak. Bausch Health Companies Inc. has a Quality Score of 76, which is Strong.

The Quality Grade Winner: Bausch Health Companies Inc.

As you can clearly see from the Quality Grade breakdown above, Bausch Health Companies Inc. has a better overall quality grade than Immunocore Holdings plc. For investors who are looking for companies with higher quality than others in the same industry, Bausch Health Companies Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Immunocore Holdings plc and Bausch Health Companies Inc. Grades

In addition to Quality, Value and Growth, A+ Investor also provides grades for Momentum and Estimate Revisions.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Immunocore Holdings plc and Bausch Health Companies Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Immunocore Holdings plc or Bausch Health Companies Inc. Stock?

Overall, Immunocore Holdings plc stock has a Value Score of 19, Growth Score of 26 and Quality Score of 29.

Bausch Health Companies Inc. stock has a Value Score of 95, Growth Score of 40 and Quality Score of 76.

Comparing Immunocore Holdings plc and Bausch Health Companies Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.